Every year over 60,000 people go blind from diabetic retinopathy, a complication of diabetes that can be prevented if diagnosed in the early stages. However, as few as 15% of people living with diabetes receive an annual eye exam for diabetes.
The solution: Digital Diagnostics’ flagship product, LumineticsCore™.
LumineticsCore is the first FDA-cleared autonomous AI diagnostic system designed to detect diabetic retinopathy (including macular edema), a common complication of diabetes and a leading cause of blindness. LumineticsCore provides an autonomous diagnosis at the point-of-care, allowing for increased patient access and expanded offerings by non-eyecare providers. LumineticsCore is the flagship product in Digital Diagnostics’ vision to break down barriers in healthcare and create a future where ethically founded autonomous AI systems improve access to quality healthcare and improve patient outcomes.